Match Application Now Open for the FY2026-27 Fellowship Year. For Fellowships beginning: July 2026Application Period: Monday, December 16, 2024 – Monday, March 3, 2025Interview Period: Monday, March 3, 2025– Monday, June 23, 2025Ranking list opens for Programs and Applicants: Monday, June 23, 2025Ranking list closes: Monday, July 7, 2025Match results announced: Friday, July 11, 2025 […]
Belantamab mafodotin plus bortezomib/dexamethasone improved OS over daratumumab plus bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
CAN-2409 plus valacyclovir and radiation therapy significantly improved DFS in intermediate- to high-risk localized prostate cancer.
Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.
With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in treating acute myeloid leukemia with mutations in measurable…
Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.
Join us for a virtual session where learners will hear from experts in the field in a didactic & panel case discussion format.
The addition of uproleselan to chemotherapy did not meet the primary OS end point of a phase 3 trial evaluating patients with relapsed/refractory AML.
